Natalizumab for active Crohn's disease

New England Journal of Medicine

Volumn 348, Issue 1, 2003, Pages 24-32

  Ghosh, Subrata ^a,j   Goldin, Eran ^b   Gordon, Fiona H ^c   Malchow, Helmut A ^d   Rask Madsen, Jørgen ^e   Rutgeerts, Paul ^f   Vyhnálek, Petr ^g   Zádorová, Zdena ^h   Palmer, Tanya ⁱ   Donoghue, Stephen ⁱ  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d KLINIKUM LEVERKUSEN   (Germany)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g Pardubice Regional Hospital   (Czech Republic)

^h Teaching Hospital Kralovske Vinohrady   (Czech Republic)

ⁱ Elan Pharmaceuticals   (United Kingdom)

^j HAMMERSMITH HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; C REACTIVE PROTEIN; NATALIZUMAB; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INFECTION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; QUALITY OF LIFE; REMISSION INDUCTION;

EID: 0037413468     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa020732     Document Type: Article

References (24)

1. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994;76:301-14.
2. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272:60-6.
3. Damle NK, Klussman K, Leytze G, Aruffo A, Linsley PS, Ledbetter JA. Costimulation with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 augments activation-induced death of antigen-specific CD4+ T lymphocytes. J Immunol 1993;151:2368-79.
4. Koopman G, Keehnen RM, Lindhout E, et al. Adhesion through the LFA-1 (CD11a/ CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol 1994;152:3760-7.
5. Leussink VI, Zettl UK, Jander S, et al. Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis. Acta Neuropathol (Berl) 2002;103:131-6.
6. Lobb RR, Hemler ME. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 1994;94:1722-8.
7. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993;11:767-804.
8. Postigo AA, Teixido J, Sanchez-Madrid F. The alpha 4 beta 1/VCAM-1 adhesion pathway in physiology and disease. Res Immunol 1993;144:723-35.
9. Farstad IN, Halstensen TS, Kvale D, Fausa O, Brandtzaeg P. Topographic distribution of homing receptors on B and T cells in human gut-associated lymphoid tissue: Relation of L-selectin and integrin alpha 4 beta 7 to naive and memory phenotypes. Am J Pathol 1997;150:187-99.
10. Issekutz TB. Inhibition of in vivo lymphocyte migration to inflammation and homing to lymphoid tissues by the TA-2 monoclonal antibody: A likely role for VLA-4 in vivo. J Immunol 1991;147:4178-84.
11. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110.
12. Johnston B, Walter UM, Issekutz AC, Issekutz TB, Anderson DC, Kubes P. Differential roles of selectins and the alpha4-integrin in acute, subacute, and chronic leukocyte recruitment in vivo. J Immunol 1997;159:4514-23.
13. Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest 1993;92:372-80.
14. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996;111:1373-80.
15. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74.
16. Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to α4 integrin. Aliment Pharmacol Ther 2002;16:699-705.
17. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development ofa Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
18. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979;77:847-69.
19. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-96.
20. Landis RJ, Heyman ER, Koch GG. Average partial association in three-way contingency tables: A review and discussion of alternative tests. Int Stat Rev 1978;46:237-54.
21. Jennrich RI, Schluchter MD. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986;42:805-20.
22. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
23. Sandborn WJ. Transcending conventional therapies: The role of biologic and other novel therapies. Inflamm Bowel Dis 2001;7:Suppl 1:S9-S16.
24. Stein RB, Lichtenstein GR. Medical therapy for Crohn's disease: The state of the art. Surg Clin North Am 2001;81:71-101.